Many adults stop GLP-1 therapy within a year with low restart rates, analysis finds

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy within one year. Discontinuation rates were significantly higher and reinitiation rates were significantly lower for patients without type 2 diabetes.